A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials

• Emmanuelle Kempf,

  Affiliation Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France

  ⨯
• Nathalie Lemoine,

  Affiliation Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France

  ⨯
• Gabrielle Tergemina-Clain,

  Affiliation Gustave-Roussy Cancer Campus, Biostatistics and Epidemiology unit, Villejuif, France

  ⨯
• Anthony Turpin,

  Affiliation Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France

  ⨯
• Sophie Postel-Vinay,

  Affiliations Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France, Université Paris Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin Bicêtre, France, Inserm Unit U981, Gustave Roussy, Villejuif, France

  ⨯
• Emilie Lanoy,

  Affiliation Gustave-Roussy Cancer Campus, Biostatistics and Epidemiology unit, Villejuif, France

  ⨯
• Jean-Charles Soria,

  Affiliations Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France, Université Paris Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin Bicêtre, France, Inserm Unit U981, Gustave Roussy, Villejuif, France

  ⨯
• Christophe Massard,

  Affiliation Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France

  ⨯
• Antoine Hollebecque

  * E-mail: antoine.hollebecque@gustaveroussy.fr

  Affiliation Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France

  ⨯